Table 2

Mean scores ± SD of the various measures of psychopathology and craving at the different time points of assessment (time 0 → time 2) in the control and the topiramate augmentation group

Variable

(Mean ± SD)

Group

1st Assessment (time 0)

2nd Assessment

(time 1)

3rd Assessment

(time 2)


HDRS


Controls

38.7 ± 7.6

15.9 ± 8.6+

8.1 ± 6.6∞


Topiramate

39.6 ± 5.5

12.5 ± 3.1*+

4.9 ± 3.1*∞


HARS


Controls

30.5 ± 10.2

13.9 ± 6.7+

7.1 ± 6.2∞


Topiramate

31.8 ± 5.3

10.9 ± 3.6*+

4.3 ± 3.8*∞


GAS


Controls

46.7 ± 5.1

75.6 ± 9.3+

85.4 ± 8.5∞


Topiramate

46.6 ± 4.7

74.3 ± 6.7+

84.3 ± 5.6∞


OCDS


Controls

37.2 ± 8.3

17.3 ± 3.9+

13.3 ± 2.8∞


Topiramate

37.6 ± 7.8

15.3 ± 3.9*+

10.3 ± 3.1**∞


Statistics: Between groups (independent samples t-test); within groups (RMANOVA)

*Significant difference between controls and topiramate augmentation group (< 0.05)

** Significant difference between controls and topiramate augmentation group (< 0.01)

+ Significant difference between 2nd and 1st assessment (< 0.01)

∞ Significant difference between 3rd and 2nd assessment (< 0.01)

Paparrigopoulos et al. BMC Psychiatry 2011 11:41   doi:10.1186/1471-244X-11-41

Open Data